Form 4: Alnylam Pharmaceuticals EVP, CFO Jeffrey V. Poulton Reports Stock Transactions

Jeffrey V. Poulton, EVP and CFO of Alnylam Pharmaceuticals, reports acquisition of restricted stock units and stock options, as well as sales of common stock to cover tax obligations.

Summary

• Jeffrey V. Poulton, the EVP and CFO of Alnylam Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On March 3, 2025, Poulton acquired 15,117 restricted stock units (RSUs) and 9,800 stock options.
• The RSUs vest over three years, with one-third vesting annually, contingent on continued service.
• The stock options vest as to 25% of the shares on the first anniversary of the grant date and the remaining shares vest in equal installments at the end of each successive three-month period thereafter until the fourth anniversary of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date.
• Poulton also sold 904 shares of common stock to cover tax withholding obligations, at prices ranging from $242.37 to $248.36.
• Following these transactions, Poulton directly owns 47,751 shares of common stock and indirectly owns 57 shares through a managed account.
• He also holds 9,800 stock options and unvested RSUs.

Sentiment

Score: 6

Explanation: Neutral sentiment. The filing reflects routine transactions related to executive compensation and tax obligations. There's no indication of unusual or concerning activity.

Positives

• The acquisition of RSUs and stock options indicates confidence in the company's future performance.

Negatives

• The sale of shares, even for tax obligations, could be perceived negatively by some investors, although it's a common practice.

Risks

• The vesting of RSUs and stock options is contingent on continued service, creating a retention risk for Alnylam if Poulton were to leave the company.

Future Outlook

The vesting schedules of the RSUs and stock options suggest a long-term commitment from the executive.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors for signals about management's view of the company's prospects.

Comparison to Industry Standards

• Executive compensation packages including RSUs and stock options are standard practice in the pharmaceutical industry to align management interests with shareholder value.
• Companies like Vertex Pharmaceuticals and Regeneron Pharmaceuticals also utilize similar equity-based compensation strategies for their executives.
• The vesting schedules and exercise prices are generally in line with industry norms for companies of Alnylam's size and stage of development.

Stakeholder Impact

• The transactions have a minor impact on shareholders, primarily through the potential dilution from the vesting of RSUs and exercise of stock options.

Key Dates